PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
The Poly (ADP-ribose) polymerase (PARP) family has many essential functions in cellular processes, including the regulation of transcription, apoptosis and the DNA damage response. PARP1 possesses Poly (ADP-ribose) activity and when activated by DNA damage, adds branched PAR chains to facilitate the...
Main Authors: | Maddison Rose, Joshua T. Burgess, Kenneth O’Byrne, Derek J. Richard, Emma Bolderson |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-09-01
|
Series: | Frontiers in Cell and Developmental Biology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fcell.2020.564601/full |
Similar Items
-
PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies
by: Elizabeth K. Lee, et al.
Published: (2020-07-01) -
Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer
by: Jacob J. Adashek, et al.
Published: (2019-08-01) -
Integration of PARP-inhibitors in ovarian cancer therapy
by: Antonella Pietragalla, et al.
Published: (2020-06-01) -
Resistance to PARP-inhibitors in Cancer Therapy
by: Alicia eMontoni, et al.
Published: (2013-02-01) -
Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status
by: Angiolo Gadducci, et al.
Published: (2019-01-01)